Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 4/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.55 |
| ▸ | ALOX12 | P18054 | 2/20 | 0.55 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.48 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.48 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.47 |
| ▸ | GRM5 | P41594 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 5/20 | 0.46 |
| ▸ | RAB9A | P51151 | 5/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.41 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.41 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.41 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.41 |
| ▸ | AURKA | O14965 | 1/20 | 0.41 |
| ▸ | FDPS | P14324 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3245214 | 0.81 | HAO1 (0.47) | MEN1KMT2AGRM5NPC1RAB9A | |
| SCHEMBL4516270 | 0.81 | NPC1 (0.62) | MEN1KMT2AGRM5NPC1RAB9A | |
| SCHEMBL2280918 | 0.81 | ALDH1A1 (0.60) | MEN1KMT2AGRM5NPC1RAB9A | |
| SCHEMBL31532396 | 0.81 | ALDH1A1 (0.60) | MEN1KMT2AGRM5NPC1RAB9A | |
| SCHEMBL22452592 | 0.81 | CHRNB4 (0.51) | CHRNB4CHRNA3 | |
| SCHEMBL355054 | 0.80 | ALDH1A1 (0.50) | MEN1KMT2ANPC1RAB9ALMNA | |
| SCHEMBL180474 | 0.78 | ABL1 (0.48) | MEN1KMT2AALOX12NPC1RAB9A | |
| SCHEMBL24308132 | 0.78 | RAB9A (0.62) | MEN1KMT2AALOX12CHRNB4CHRNA3 | |
| SCHEMBL912815 | 0.78 | KMT2A (0.55) | MEN1KMT2AALOX12CHRNB4CHRNA3 | |
| SCHEMBL25325312 | 0.77 | NPC1 (0.46) | MEN1KMT2ANPC1RAB9ALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8642620-B2 | Heteroaryl-substituted amides comprising an unsaturated or cyclic linker group, and their use as pharmaceuticals | SANOFI (FR) | 2014-02-04 | — | — | US | disclosed |
| CN-101213184-B | Heteroaryl-substituted amides comprising an unsaturated or cyclic linking group and their use as medicaments | SANOFI AVENTIS | 2011-05-25 | — | — | CN | disclosed |
| EP-1904476-B1 | HETEROARYL-SUBSTITUTED AMIDES COMPRISING AN UNSATURATED OR CYCLIC LINKER GROUP, AND THEIR USE AS PHARMACEUTICALS | SANOFI AVENTIS (FR) | 2009-02-25 | — | — | EP | disclosed |
| US-20080167342-A1 | Heteroaryl-Substituted Amides Comprising An Unsaturated Or Cyclic Linker Group, And Their Use As Pharmaceuticals | SANOFI-AVENTIS (FR) | 2008-07-10 | — | — | US | disclosed |
| CN-101213184-A | Heteroaryl-substituted amides comprising an unsaturated or cyclic linking group and their use as medicaments | SANOFI AVENTIS (FR) | 2008-07-02 | — | — | CN | disclosed |
| EP-1904476-A1 | HETEROARYL-SUBSTITUTED AMIDES COMPRISING AN UNSATURATED OR CYCLIC LINKER GROUP, AND THEIR USE AS PHARMACEUTICALS | Sanofi-Aventis (FR) | 2008-04-02 | — | — | EP | disclosed |
| EP-1741708-A1 | Heteroaryl-substituted amides comprising an unsaturated or cyclic linker group, and their use as pharmaceuticals | Sanofi-Aventis Deutschland GmbH (DE) | 2007-01-10 | — | — | EP | disclosed |
| WO-2007000248-A1 | HETEROARYL-SUBSTITUTED AMIDES COMPRISING AN UNSATURATED OR CYCLIC LINKER GROUP, AND THEIR USE AS PHARMACEUTICALS | SANOFI-AVENTIS (DE) | 2007-01-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080167342-A1 | Heteroaryl-Substituted Amides Comprising An Unsaturated Or Cyclic Linker Group, And Their Use As Pharmaceuticals | TBXAS1, PTGIS, NOS2 | MEN1 3988/4885KMT2A 2212/4885ALOX12 14/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.